Breast Cancer Therapeutics
APAC
APAC Psychedelic Therapeutics Market Industry Trends and Forecast to 2034: Segmented by (Compound, Indication, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Overview
APAC · 2024–2034 · estimates
Market Dashboard
Values shown here are estimates. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Estimate 2024
$668.7 Mn
Estimated value
Estimate 2025
$765.0 Mn
20% of the global market
Projected 2034
$2.57 Bn 235.6%
Adds $1.80 Bn over 9 forecast years
CAGR 2025–2034
14.4%
Faster than 72% of 180 Pharmaceuticals markets here
Key players
5
Companies profiled
- APAC is 19.97% of the global market.
- Among regions, the largest is North America at $2.06 Bn.
- Fastest growing: APAC (this report) at 14.4% a year.
- APAC ranks 2nd of 6 by size among regions.
Market size projection
APACSource: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
Value added each year
$1.80 Bn total, 2026–2034
Year-by-year market size, 2024–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $668.7 Mn | — | — |
| 2025 (base) | $765.0 Mn | +$96.3 Mn | — |
| 2026 (forecast) | $875.1 Mn | +$110.2 Mn | +14.4% |
| 2027 (forecast) | $1.00 Bn | +$126.0 Mn | +30.9% |
| 2028 (forecast) | $1.15 Bn | +$144.2 Mn | +49.7% |
| 2029 (forecast) | $1.31 Bn | +$164.9 Mn | +71.3% |
| 2030 (forecast) | $1.50 Bn | +$188.7 Mn | +95.9% |
| 2031 (forecast) | $1.71 Bn | +$215.8 Mn | +124.2% |
| 2032 (forecast) | $1.96 Bn | +$246.9 Mn | +156.4% |
| 2033 (forecast) | $2.24 Bn | +$282.5 Mn | +193.4% |
| 2034 (forecast) | $2.57 Bn | +$323.2 Mn | +235.6% |
Estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
Same market worldwide
By geography
- Global $3.83 Bn
- North America $2.06 Bn
-
US
$1.55 Bn
- APAC (this report) $765.0 Mn
- Europe $709.6 Mn
-
China
$325.4 Mn
-
Canada
$276.7 Mn
-
Japan
$237.6 Mn
- Latin America $163.3 Mn
- Middle East $151.4 Mn
-
Germany
$120.6 Mn
-
UK
$109.5 Mn
-
France
$108.8 Mn
-
Italy
$101.7 Mn
-
Brazil
$88.9 Mn
-
Ecuador
$78.0 Mn
-
India
$80.7 Mn
-
Saudi Arabia
$71.7 Mn
-
Spain
$67.7 Mn
-
Mexico
$65.2 Mn
- Africa $66.4 Mn
-
Australia
$45.3 Mn
-
New Zealand
$42.8 Mn
-
Russia
$33.5 Mn
-
South Africa
$24.5 Mn
-
UAE
$18.5 Mn
-
Egypt
$9.8 Mn
-
Philippines
$8.0 Mn
-
Hong Kong
$6.3 Mn
-
Malaysia
$5.4 Mn
-
Thailand
$5.3 Mn
-
Singapore
$5.0 Mn
-
Kenya
$2.5 Mn
The APAC Psychedelic Therapeutics Market Analysis Executive Summary
Psychedelic therapeutics use compounds such as psilocybin, MDMA and LSD with therapy support to treat depression, PTSD and addiction.
Key segments of the psychedelic Therapeutics market include compound (Psilocybin, MDMA and LSD) and indication (Treatment-Resistant Depression, PTSD and Substance Use Disorder).
APAC Psychedelic Therapeutics Market Dynamics
Market Growth Drivers
More people seeking help for mental health, less stigma, better screening and new treatments with faster effects are driving the psychedelic Therapeutics market. Governments and employers are investing more in mental health care.
Opportunity
Digital tools, new drug classes and care built into primary care and workplaces give the psychedelic Therapeutics market strong room to grow worldwide.
Market Restraints
Shortages of mental health professionals, limited insurance coverage, side effects and the need for long-term treatment hold back the psychedelic Therapeutics market.
Competitive Landscape for Psychedelic Therapeutics Market in APAC
The psychedelic Therapeutics market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Key Players
Healthcare Policies and Regulatory Landscape for Psychedelic Therapeutics Market in APAC
Policy changes and Reimbursement scenario
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for psychedelic Therapeutics. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in APAC.
From our blog
Adaptogens: Ancient Herbs, Modern Market170 WHO Member States report the use of traditional medicine. Adaptogens like ashwagandha, rhodiola and…
Stress and Mood Supplements: Ashwagandha and BeyondDepression and anxiety cost the world about US$1 trillion a year. Ashwagandha has some evidence for stress…
Antidepressants: Demand, Access and New ApproachesAbout 322 million people live with depression. Treatment works, but most people still do not get it.